New study identifies compounds that could slow down Alzheimer's disease

A family of naturally occurring plant compounds could help prevent or delay memory loss associated with Alzheimer's disease, according to a new study by the Translational Genomics Research Institute (TGen).

Beta-carboline alkaloids could potentially be used in to stop, or at least slow down, the progressively debilitating effects of Alzheimer's, according to the study published recently in the scientific journal Public Library of Science (PLoS) One.

One of these alkaloids, called harmine, inhibits a protein known as DYRK1A, which has been implicated by this and other studies in the formation tau phosphorylation. This process dismantles the connections between brain cells, or neurons, and has been linked in past studies to Alzheimer's disease.

Tau is a protein critical to the formation of the microtubule bridges in neurons. These bridges support the that, like computer circuits, allow brain cells to communicate with each other.

"Pharmacological inhibition of DYRK1A through the use of beta-carboline alkaloids may provide an opportunity to intervene therapeutically to alter the onset or progression of tau pathology in Alzheimer's disease," said Dr. Travis Dunckley, Head of TGen's Neurodegenerative Research Unit, and the study's senior author.

Beta-carboline alkaloids are found in a number of medicinal plants. They have , and have been shown to protect brain cells from excessive stimulation of neurotransmitters. "(They) are natural occurring compounds in some plant species that affect multiple targets," the study said.

Under normal circumstances, proteins regulate tau by adding phosphates. This process of tau phosphorylation enables connections between brain cells to unbind and bind again, allowing neurons to connect and reconnect with other . However, this process can go awry, allowing the formation of neurofibrillary tangles, one of the signature indicators of Alzheimer's.

In this study, laboratory tests showed that harmine, and several other beta-carboline , "potently reduced'' the expression of three forms of phosphorylated tau, and inhibited the ability of DYRK1A to phosphorylate tau protein at multiple genetic sites associated with tau pathology.

"These results suggest that this class of compounds warrant further investigation as candidate tau-based therapeutics to alter the onset or progression of tau dysfunction and pathology in Alzheimer's disease," Dr. Dunckley said.

The Arizona Alzheimer's Consortium, the National Institute on Aging, and the Louis Charitable Trust funded the study. The Consortium is funded in part by the Arizona Legislature through the Arizona Department of Health Services, which supported a portion of the study. Members of the Consortium also participated in the study. MediProPharma Inc. supported portions of the study.

Provided by The Translational Genomics Research Institute

3 /5 (1 vote)

Related Stories

Recommended for you

Student seeks to improve pneumonia vaccines

8 hours ago

Almost a million Americans fall ill with pneumonia each year. Nearly half of these cases require hospitalization, and 5-7 percent are fatal. Current vaccines provide protection against some strains of the ...

Seabed solution for cold sores

10 hours ago

The blue blood of abalone, a seabed delicacy could be used to combat common cold sores and related herpes virus following breakthrough research at the University of Sydney.

Better living through mitochondrial derived vesicles

Aug 19, 2014

(Medical Xpress)—As principal transformers of bacteria, organelles, synapses, and cells, vesicles might be said to be the stuff of life. One need look no further than the rapid rise to prominence of The ...

Zebrafish help to unravel Alzheimer's disease

Aug 19, 2014

New fundamental knowledge about the regulation of stem cells in the nerve tissue of zebrafish embryos results in surprising insights into neurodegenerative disease processes in the human brain. A new study by scientists at ...

User comments